Nucleosides and nucleotides: natural bioactive substances in milk and colostrum

Eckhard Schlimme*, D. Martin and H. Meisel
Bundesanstalt für Milchforschung, Institut für Chemie und Physik, Kiel, Germany

Nucleotides, nucleosides and nucleobases belong to the non-protein-nitrogen (NPN) fraction of milk. The largest amounts of ribonucleosides and ribonucleotides – ribose forms only were considered in this review – were measured directly after parturition in bovine milk and other ruminants as well as in the milk of humans. Generally, concentrations of most of the nucleos(t)ides tend to decrease gradually with advancing lactation period or nursing time. The species-specific pattern of these minor constituents in milk from different mammals is a remarkable property and confirms, at least, the specific physiological impact of these minor compounds in early life. The physiological capacity of these compounds in milk is given by the total potentially available nucleosides. The main dietary sources of nucleos(t)ides are nucleo-proteins and nucleic acids which are converted in the course of intestinal digestion into nucleosides and nucleobases the preferred forms for absorption in the intestine. Thus, nucleosides and nucleobases are suggested to be the acting components of dietary and/or supplemented nucleic acid-related compounds in the gut. They are used by the body as exogenous trophochemical sources and can be important for optimal metabolic functions. Up to 15% of the total daily need for a breast-fed infant was calculated to come from this dietary source. Concerning their biological role they not only act as metabolites but are also involved as bioactive substances in the regulation of body functions. Dietary nucleotides affect immune modulation, e.g. they enhance antibody responses of infants as shown by a study with more than 300 full-term healthy infants. Dietary nucleos(t)ides are found to contribute to iron absorption in the gut and to influence desaturation and elongation rates in fatty acid synthesis, in particular long-chain polysaturated fatty acids in early stages of life. The in vitro modulation of cell proliferation and apoptosis has been described by ribonucleosides, in particular by modified components using human cell culture models. Due to the bio- and trophochemical properties of dietary nucleos(t)ides, the European Commission has allowed the use of supplementation with specific ribonucleotides in the manufacture of infant and follow-on formula. From the technochemical point of view, the ribonucleoside pattern is influenced by thermal treatment of milk. In addition ribonucleosides are useful indicators for quantifying adulterations of milk and milk products.

Nucleosides and nucleotides: Bioactive substances: Milk and colostrum

Introduction

Nucleotides, nucleosides and nucleobases, occurring in the sub-milligram range per litre, belong to the non-protein-nitrogen (NPN) fraction of milk. The terms nucleoside and nucleotide will consider only ribose forms in this review. Although specific compositions of milk ribonucleotides have been described for several mammalian species by different authors since the late 1950s (Manson, 1956; Johke & Goto, 1962; Larson, 1976; Gil & Sanchez-Medina, 1981a,b) and although their role as dietary modulators is of current interest concerning the supplementation of infant formula with individual ribonucleotides (Gil et al. 1988; Commission Directive, 1996), it was only during the last decade that the ribonucleosides have become an object of food research (Tiemeyer et al. 1984; Schlimme et al. 1986, 1991, 1997b; Raezke et al. 1988; Raezke & Schlimme, 1990; Groß et al. 1992; Schneehagen & Schlimme, 1992; Topp et al. 1993; Schlimme & Schneehagen, 1995). The species-specific concentration pattern of

Abbreviations: Ado, adenosine; m1Ado, 1-methyladenosine; m6Ado, N6-methyladenosine; m6,2Ado, N6,2-dimethyladenosine; ip6Ado, N6-(2-isopentenyl)-adenosine; t6Ado, N6-carbamoyl-L-threonyladenosine; Guo, guanosine; m1Guo, 1-methylguanosine; m2Guo, N2-methylguanosine; m2,2Guo, N2-dimethylguanosine; Cyd, cytidine; Ino, inosine; m1Ino, 1-methylinosine; m1Ino, 1-methylinosine; m1Ino, 1-methylinosine; m7Ino, 7-methylinosine; Urd, uridine; 5'-AMP, adenosine-5'-monophosphate; 5'-CMP, cytidine-5'-monophosphate; 5'-GMP, guanosine-5'-monophosphate; 5'-IMP, inosine-5'-monophosphate; 5'-UMP, uridine-5'-monophosphate.

* Corresponding author: Professor E. Schlimme, fax +49 431 609-2300, email schlimme@bafm.de
the milk constituents shows the species-specific physiological relevance of these minor compounds for the neonate. It is generally taken for granted that these species-specific concentration patterns are physiologically relevant as otherwise the evolutional process would have resulted in elimination of the species-specific pattern of this substance.

### Compositional aspects

**Ribonucleosides**

A reported study on the concentration levels and pattern of ribonucleosides in raw bovine milk throughout a lactation period under defined feeding conditions has shown that, with the exception of the colostral phase, the levels of these minor milk constituents vary only slightly (Raezke & Schlimme, 1990; Schlimme et al. 1991). From all measured values for a given ribonucleoside it appears that the nucleoside concentration decreases during the colostral phase and reaches a constant level approximately three weeks postpartum (d).

### Table 1. Ribonucleosides (μmol/l)* in bovine milk and colostrum

<table>
<thead>
<tr>
<th></th>
<th>Ado</th>
<th>Cyd</th>
<th>Guo</th>
<th>Ino</th>
<th>Urd</th>
<th>m1Ado</th>
<th>t6Ado</th>
<th>Ado+Ino</th>
</tr>
</thead>
<tbody>
<tr>
<td>c1a</td>
<td>2.0</td>
<td>11.6</td>
<td>2.1</td>
<td>4.7</td>
<td>132.6</td>
<td>1.0</td>
<td>2.9</td>
<td>6.7</td>
</tr>
<tr>
<td>c1b</td>
<td>2.6</td>
<td>6.0</td>
<td>2.0</td>
<td>2.9</td>
<td>58.2</td>
<td>0.5</td>
<td>1.1</td>
<td>5.5</td>
</tr>
<tr>
<td>c1c</td>
<td>2.4</td>
<td>4.0</td>
<td>1.5</td>
<td>1.5</td>
<td>25.6</td>
<td>0.5</td>
<td>0.8</td>
<td>3.9</td>
</tr>
<tr>
<td>c1d</td>
<td>1.4</td>
<td>2.4</td>
<td>0.8</td>
<td>1.0</td>
<td>14.7</td>
<td>0.4</td>
<td>0.7</td>
<td>2.4</td>
</tr>
</tbody>
</table>

* Values taken from Raezke & Schlimme (1990), details with respect to the automated operation of the ribonucleoside analyzer are described elsewhere (Raezke & Schlimme, 1990; Schlimme & Boos, 1990; Schlimme et al. 1991). Each mean value is the arithmetic mean of determinations (in duplicate) in the first (a), second (b) and third (c) lactation week postpartum as well as throughout the whole lactation period with the exception of the first 3 weeks postpartum (d).

### Table 2. Ribonucleosides in mature human milk

<table>
<thead>
<tr>
<th></th>
<th>Ado</th>
<th>Cyd</th>
<th>Guo</th>
<th>Urd</th>
<th>m1Ado</th>
<th>t6Ado</th>
<th>m1Guo</th>
</tr>
</thead>
<tbody>
<tr>
<td>μmol/l*</td>
<td>5.3</td>
<td>4.3</td>
<td>0.2</td>
<td>0.5</td>
<td>0.3</td>
<td>0.5</td>
<td>0.4</td>
</tr>
<tr>
<td>mg/l</td>
<td>1.4</td>
<td>1.0</td>
<td>0.1</td>
<td>0.1</td>
<td>0.1</td>
<td>0.2</td>
<td>0.1</td>
</tr>
<tr>
<td>μmol/l†</td>
<td>1.6</td>
<td>4.4</td>
<td>0.3</td>
<td>6.9</td>
<td>–§</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>mg/l</td>
<td>0.4</td>
<td>1.1</td>
<td>0.1</td>
<td>1.7</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>μmol/l‡</td>
<td>3.0</td>
<td>5.1</td>
<td>1.0</td>
<td>4.2</td>
<td>0.3</td>
<td>0.4</td>
<td>0.7</td>
</tr>
<tr>
<td>mg/l</td>
<td>0.8</td>
<td>1.2</td>
<td>0.3</td>
<td>1.0</td>
<td>0.1</td>
<td>0.2</td>
<td>0.2</td>
</tr>
</tbody>
</table>

* Adapted from Topp et al. (1993); values reported on m2Guo, m2,Guo and m1Guo, respectively, were all <0.1 μmol/l.
† Adapted from Leach et al. (1995).
‡ Adapted from Schneehagen & Schlimme (1992), Schlimme & Schneehagen (1995).
§ – no data published.
All values rounded to one decimal place.
tend to decrease without distinct maximum values in the course of lactation (Schlimme & Schneehagen, 1995).

**Ribonucleotides**

Common ribonucleotide contents in cow's milk at different stages of lactation have been measured after isolation by ion-exchange chromatography followed by postcolumn enzymic characterization of pooled chromatographic fractions (Gil & Sanchez-Medina, 1981a). Table 3 presents the levels of some common ribonucleoside-5'-monophosphates such as 5'-AMP, 5'-CMP, 5'-GMP and 5'-UMP found at different periods postpartum (Gil & Sanchez-Medina, 1981a). A few hours after parturition (2 h) a very low content of ribonucleotides was found, whereas after about 1 day postpartum (27 h) the ribonucleotide contents reached a maximum which decreased gradually as lactation continued (Gil & Sanchez-Medina, 1981a, b). This pattern is also valid with regard to the total amount of ribonucleotides, i.e. including ribonucleoside-5'-mono-, di- and triphosphates (ΣA, ΣC, ΣG, ΣU) as well as UDP-galactose and -glucose (Gil & Sanchez-Medina, 1981b). At two days postpartum the following concentration levels (μmol/l) have been described: ΣA = 67.8, ΣC = 60.5, ΣG = 36.5, ΣU = 1495.0, UDP-galactose = 320.2, UDP-glucose = 362.3. Orotic acid is the main nucleotide-related compound in bovine milk, its concentration increases with advancing lactation by about one order of magnitude and reaches a level of about 400 μmol/l 6 months after parturition (Gil & Sanchez-Medina, 1981b).

The concentration of common ribonucleotides is about one to two orders of magnitude higher than that of common ribonucleosides (Gil & Sanchez-Medina, 1981a; Raezke & Schlimme, 1990; Schlimme et al. 1991). 5'-AMP and 5'-CMP have been found to be present in all milk samples from colostral to mature stages of lactation, whereas 5'-UMP has not been detected later than 3 weeks post partum. 5'-GMP has been reported to be practically absent from bovine milk. The results reported by Gil & Sanchez-Medina (1981a) agree with former findings described, e.g. by Johke & Goto (1962).

Nucleotides were isolated from human milk for the first time in the early 1960s (Deutsch & Nilsson, 1960; Kobata, 1963). Widely fluctuating concentrations of ribonucleotides (4–70 mg/l corresponding to 10–200 μmol/l) have been reported from subsequent studies (Deutsch & Nilsson, 1960; Kobata, 1963; Gil & Sanchez-Medina, 1982; Janas & Picciano, 1982), in part at least dependent on different analytical procedures used for quantification. Gil & Sanchez-Medina (1982) give concentration data found for ribonucleotides at different stages of lactation in human milk (Table 4). Most of the data show that cytosine and uracil nucleotides comprise the largest fractions of the nucleotide content. These findings agree well with the ribonucleotide pattern (Table 2). Gil & Sanchez-Medina (1982) report on contents of UDP-galactose and -glucose which are about 10 μmol/l for both UDP-sugars and vary only slightly throughout lactation. All in all, the total ribonucleotide content is higher in human than in ruminant milk (Molina et al. 1996). Orotic acid is present in the milk of ruminants but not in human milk.

Although nucleoside and nucleotide analyses have been performed for years, there are only a small number of studies that have collected quantitative data about all the nucleo(s)ide sources, as there are nucleoproteins, nucleic acids and nucleo(s)ide derivatives, including coenzymes, which can all contribute to the nucleo(s)ide content in body fluids. Leach et al. (1995) have defined the nucleoside content, analytically accessible via the aforementioned approaches, as the 'total potentially available nucleosides' TPAN (Table 5). The mean contents of individual nucleosides in colostrum, transitory and mature human milk from 100 women in childbed from Europe (Germany, France, Italy) were taken into account at establishing the mean value (Leach et al. 1995). In the USA the mean values of the four nucleosides of eleven women in childbed were found by Leach et al. (1995) to be within the variation limit of the European proband collective.

In Table 5, in addition to ribonucleotides and ribonucleosides, the TPAN values for human milk (Leach et al. 1995) are represented, including the contents of ribonucleo(s)ides and of oligo- and polymeric ribonucleic acids (RNA). The TPAN content, partially stemming from ribonucleic acids, was significantly different with regard to the four individual nucleosides, and reflected above all the relevance of adenine nucleotides in bioenergetics and biosynthesis. Inosine was detected in human milk in concentrations one order of magnitude smaller than that of the TPAN contents of the other four nucleosides. In most of the milk samples no inosine was found (Leach et al. 1995).

![Table 3. Ribonucleotides (μmol/l) * in bovine milk at different stages of lactation](https://www.cambridge.org/core/core/terms)

<table>
<thead>
<tr>
<th>Time postpartum</th>
<th>0–1 d</th>
<th>1–2 d</th>
<th>5–10 d</th>
<th>1 month</th>
<th>2 months</th>
</tr>
</thead>
<tbody>
<tr>
<td>5'-AMP</td>
<td>39.7</td>
<td>61.8</td>
<td>41.9</td>
<td>27.5</td>
<td>20.3</td>
</tr>
<tr>
<td>5'-CMP</td>
<td>31.9</td>
<td>52.5</td>
<td>47.4</td>
<td>33.2</td>
<td>18.9</td>
</tr>
<tr>
<td>5'-UMP</td>
<td>186.3</td>
<td>390.0</td>
<td>31.2</td>
<td>n.d.</td>
<td>n.d.</td>
</tr>
</tbody>
</table>

* n.d., not detectable.

* Values taken from Gil & Sanchez-Medina (1981a).

![Table 4. Ribonucleotides in mature human milk*](https://www.cambridge.org/core/core/terms)

<table>
<thead>
<tr>
<th></th>
<th>5'-AMP</th>
<th>5'-CMP</th>
<th>5'-GMP</th>
<th>5'-UMP</th>
</tr>
</thead>
<tbody>
<tr>
<td>μmol/l</td>
<td>7.8</td>
<td>7.0</td>
<td>1.2</td>
<td>4.8</td>
</tr>
</tbody>
</table>

* Adapted from Gil & Sanchez-Medina (1982).

† 1 month postpartum; values given as disodium salt.

Values (rounded to the nearest whole number) taken from: *Schlimme & Schneehagen (1995); †Gil & Sanchez-Medina (1982); ‡Leach et al. (1995).
1995). These results are confirmed by investigations of Japanese human milk samples, in which 5'-GMP and 5'-IMP could only be detected in a few samples (Sugawara et al. 1995).

Based on the presented results, the quantity of nucleotides or nucleosides to be added to infant formula to obtain TPN contents similar to those in mature human milk can be evaluated. This would allow the advantageous properties of nucleotide(s)ides would be made available to non-breast-fed infants via ingestion of supplemented infant formula (see below).

For a better evaluation of the concentration level of ribonucleosides in human milk (Table 2) the nutrient density (µg/MJ) of these minor compounds should be compared to that of certain vitamins in milk: vitamin A (239) (Souci et al. 1994), adenosine (278), cytidine (417), nicotinamide (589) (Souci et al. 1994).

Trophochemical aspects

Nucleotides play key roles in nearly all biochemical processes in cell metabolism and are the monomeric precursors of nucleic acids. Nucleotides are provided by either endogenous biochemical sources – de novo synthesis and/or salvage pathway – or by exogenous trophochemical sources, i.e. by dietary supply.

Dietary nucleotides are ingested mainly as nucleoproteins (Uauy, 1989, Uauy et al. 1996) and are converted in the course of intestinal digestion into monomeric compounds. Nucleosides and nucleobases are translocated across the plasma membrane by specified facilitated-diffusion carriers and sodium-dependent transporters (Plagemann & Wohlrheuter, 1984; Arnow et al. 1986; Bronk & Hastewell, 1987; Ullman et al. 1987; Belt & Noel, 1998; Vijayalakshmi et al. 1992; Griffith & Jarvis, 1993; Jarvis, 1996) located in intestinal and kidney epithelial cells (Le Hir & Dubach, 1985; Darnowski et al. 1987; Lee et al. 1988; Jarvis, 1989; Williams & Jarvis, 1991; Gutiérrez et al. 1992). When nucleoproteins and/or nucleotides are fed, there is evidence that the gut will activate the transcription of enzymes responsible for the salvage pathway, in particular in the upper intestine. It is known that some tissues such as the intestinal mucosa and bone haematopoietic cells preferentially utilize the salvage pathway due to limited capacity for de novo synthesis (Uauy, 1989), i.e. for these cells the exogenous supply of nucleic acid derived components can be important for optimal functions. From this view nucleotides and related compounds have been recognized to be semiessential (Uauy, 1989; Molina et al. 1996).

Uauy (1989) has calculated to what extent preformed dietary nucleotides can cover the total body need of these components. He has estimated a nucleotide pool of 9–15 g per kg body weight of a full-term newborn. Considering a daily growth rate of 10 g/kg an accretion rate of total nucleotides for a 3 kg infant would be approximately 12 mg nucleotides per g body weight gain. The ingestion of milk nucleotides for a breast-fed newborn was calculated to be less than 2 % of daily needs and up to 15 %, if dietary nucleic acids are considered (Uauy, 1989). Uauy (1989) concluded that ‘nucleotides may have potential effects on gut and related tissues, which would be most important to their influence, but would not be likely to have systemic effects given the very small contribution of dietary supply to overall nucleotide economy’.

The presence of specific nucleos(t)ides in human milk may be a factor in the immune response of breast-fed infants (Gyorgy, 1971) and are suggested as growth factors for the neonate (Barness & Carver, 1996). However, clinical studies with nucleotide supplemented formula have not shown detectable effects on weight gain, linear growth and other anthropometric indices of growth (Uauy, 1989 and cited references).

In this context Pickering et al. (1998) investigated whether human milk and ribonucleotides added to infant formula at levels present in human milk enhance infant immunity as measured by antibody response to immunization. A total of 370 full-term healthy infants were enrolled in the study. They were divided into three groups for a period of 12 months; 311 infants (84 %) completed the study. The control group (125/107 infants, 46 % female) were given a milk-based control formula and the nucleotide group (121/101; 42 % female) the same formula fortified with 73 mg nucleotides/l. The target level of fortification was based on that of human milk (Leach et al. 1995) and was adjusted to 31.2 mg 5'-CMP; 17.7 mg 5'-UMP, 9.8 mg 5'-AMP, and 14.4 mg 5'-GMP per litre in the nucleotide formula (see Table 6). The third group were fed human milk (124/103; 54 % female) for 2 months and then further on exclusively human milk or Similac®-formula with iron (Ross Lab., Columbus, USA) until 12 months of age. As a parameter for the development of the infants’ immune system the vaccination reaction was followed up for the first year of life. According to specifications of the American Academy of Pediatrics, the vaccinations against infections by Haemophilus influenzae, diphtheria, tetanus and oral polio virus were performed at the ages of 2, 4 and 6 months. During the sixth, seventh and twelfth months the antibody responses were determined. The Pickering et al. (1998) study closed with the following conclusion: ‘Infant formula fortified with nucleotides enhanced Haemophilus influenzae and diphtheria humoral antibody responses. Feeding human milk caused an enhanced antibody response to oral polio virus.’

The aforementioned study collected data on diarrhoea illness and showed that the ingestion of nucleotide-fortified formula or human milk was associated with a significant decrease in the incidence of diarrhoea when compared to the control group (Pickering et al. 1998).

Furthermore, a series of clinical studies on adults investigated the effects of RNA supplemented enteral food in comparison with RNA-free food. These studies were primarily performed by van Buren & Rudolph (1997) and resulted in the findings that optimal patient outcome may depend on provision of dietary nucleotides during a period of stress. These data support the conclusion that dietary nucleotides are conditionally essential nutrients. In this context, a publication by Fairbairn & Litt (1922) is of interest. The paper reports on a successful subcutaneous application of Nuclein (nucleic acid) in the case of different infections showing that this compound is a valuable adjunct to other treatment of infection.
Table 6. Comparison of the supplemented quantity of nucleotides in infant formula according to the EC Directive, the nucleotide group (Pickering et al. 1998) and the supplementation recommendation (Schlimme & Martin, 1999) based on TPAN contents in human milk (Leach et al. 1995)

<table>
<thead>
<tr>
<th>Reference</th>
<th>5′-AMP (mg/100 kcal)</th>
<th>5′-CMP (mg/l)</th>
<th>5′-GMP (mg/l)</th>
<th>5′-UMP (mg/l)</th>
<th>5′-IMP (mg/l)</th>
<th>Total (mg/l)</th>
<th>Upper limit (mg/l)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Commission Directive, (1996)</td>
<td>1.50</td>
<td>2.50</td>
<td>0.50</td>
<td>1.75</td>
<td>1.00</td>
<td>7.25</td>
<td>5</td>
</tr>
<tr>
<td>(mg/l)*</td>
<td>10.4</td>
<td>17.3</td>
<td>3.5</td>
<td>12.1</td>
<td>6.9</td>
<td>50.2</td>
<td>(35)</td>
</tr>
<tr>
<td>Pickering et al. (1998)</td>
<td>9.8</td>
<td>31.2</td>
<td>14.4</td>
<td>17.7</td>
<td>–†</td>
<td>73.1</td>
<td>–†</td>
</tr>
<tr>
<td>Schlimme &amp; Martin (1999)</td>
<td>1.8</td>
<td>4.7</td>
<td>1.8</td>
<td>2.0</td>
<td>–‡</td>
<td>10.3</td>
<td>–‡</td>
</tr>
<tr>
<td>(mg/l)</td>
<td>12.5</td>
<td>32.3</td>
<td>12.6</td>
<td>14.0</td>
<td>–‡</td>
<td>71.4</td>
<td>–‡</td>
</tr>
</tbody>
</table>

* The conversion on mg nucleotide/l infant formula was calculated under the assumption that the infant formula used is isocaloric with human milk (69 kcal/100 g milk according to Souci et al. 1994); nucleotide values are given as disodium salt. † Without addition of 5′-IMP. ‡ Not recommended.

Due to the trophochemical properties of dietary nucleos(t)ides, the supplementation of infant formula and follow-on formula with nucleotides has been used for many years in some member states of the European Union as well as in third-world countries. As no negative effects related to the nucleotide supplementation are known the Commission Directive 96/4/EC (1996) allows the supplementation of infant formula with nucleotides according to concentrations given in Table 6 (Commission Directive, 1996).

Supplementation of infant formula with nucleotides and/or nucleosides should be allowed up to levels present in human milk. In evaluating the physiological capacity of nucleosides Leach et al. (1995) reported experimental findings concerning the TPAN including all mono-, oligo- and polymeric sources available in milk for the generation of these compounds via digestion and metabolism (values are given in Table 5). 5′-IMP, which was not used for nucleotide supplementation of infant formula in the Pickering et al. (1998) study, is also not mentioned in a recent recommendation (Schlimme & Martin, 1999, Table 6) due to its low TPAN portion (Leach et al. 1995).

Regarding the supplementation of infant formula with nucleotides it should be noted that the current EC Regulation (the ‘Life Science Research Office’ of the USA is working on a corresponding regulation) takes into account only those unmodified milk nucleotides that are released from mono-, oligo- and polymers during digestion and metabolism. It has not been considered that the whole TPAN content of human milk also includes the modified nucleot(s)ides that can be released in RNA breakdown reactions. The regulative potential of modified nucleotides seems to be prospective but is mainly unexplored.

Biochemical aspects

The need for nucleosides and nucleotides for chemical processes in biological systems is met by a combination of de novo synthesis and reutilization of these compounds by the salvage pathway. Whereas some systems, such as liver cells, have highly active de novo purine and pyrimidine nucleotide synthesis, other systems, such as gut epithelial cells, have limited capacity for de novo synthesis (Uauy, 1989; Uauy et al. 1990). Uauy et al. (1990) demonstrated that dietary nucleosides are able to enhance gut growth and maturation of the weaning rat. In particular, the formation of mucosal protein and mucosal DNA was found to be more pronounced in the proximal segment and the villi in this gut segment to be taller in the nucleoside-fed animal group (Uauy, 1989; Uauy et al. 1990). Furthermore, the ratio of the enzymes maltase (EC 3.2.1.20) and lactase (EC 3.2.1.23), which is an index for gut maturation, was increased in the nucleoside supplemented group (Uauy et al. 1990). Leleiko et al. (1979, 1983, 1987) have described the effect of dietary nucleotides on the activity of the enzyme hypoxanthine–guanine phosphoribosyltransferase (HGPRT) in the small intestine of rats. HGPRT is the rate-limiting enzyme in the salvage pathway of purine nucleotides (Leleiko et al. 1979, 1983, 1987; Uauy et al. 1990). Diets free from purine nucleotides and bases lower the intestinal HGPRT activity and decrease the level of messenger RNA of this salvage pathway related key enzyme (Uauy et al. 1990).

Mice fed ad libitum on chow plus water supplemented with nucleotides (3.5 mg/100 ml) for six weeks have been shown to exhibit increased natural killer cell (NK) activity in the spleen and lower macrophage activation compared to mice receiving chow alone (Carver et al. 1990). The biological effects found need further investigation to get more insight into the molecular processes induced by dietary nucleos(t)ides. From experimental findings of Barness’ group (Carver et al. 1990; Barness & Carver, 1996) it is known that infants fed with a formula supplemented with nucleotides (5′-AMP, 4 mg/l; 5′-CMP, 20 mg/l; 5′-GMP, 2 mg/l; 5′-UMP, 5 mg/l; 5′-IMP, 2 mg/l) show (in contrast to infants fed the same formula without nucleotide supplement) an immune response (natural killer cells, interleukin-2) similar to the immunological effect in breast-fed infants. These data suggest these normal milk constituents may be physiologically important.

It has been suggested that nucleos(t)ides contribute to iron absorption in the gut (McMillan et al. 1977). It was found that inosine increases intestinal uptake of iron in rats (Faelli & Esposito, 1970). Thus human milk ‘may be a factor in facilitating iron absorption in breast-fed infants’ (McMillan et al. 1977). Dietary nucleotides may also be involved in lipid metabolism (Sanchez-Pozo et al. 1986; Sanchez-Pozo & Gil, 1996) by stimulating α-lipoprotein synthesis. Plasma levels of major lipoprotein fractions have been studied in different groups of newborn infants (e.g. preterm, full-term neonates) fed on formula with and
without supplementation of nucleotides (Sanchez-Pozo & Gil, 1996). From their experimental findings Sanchez-Pozo & Gil (1996) concluded that ‘dietary nucleotides may have a positive effect on the lipoprotein metabolism of newborns by increasing HDL synthesis’. Long-chain polyunsaturated fatty acids (LC-PUFA) such as arachidonic, eicosapentaenoic and docosahexaenoic acids are important compounds in cell membrane structure. LC-PUFA are present in adequate amounts in human milk but not in adapted cow-milk-based formula. At-term infants fed with formula have lower amounts of LC-PUFA-levels in plasma, and their concentration in red blood cell membrane phospholipids has been shown to be lower than in breast-fed infants (Putnam et al. 1982; Carlson et al. 1986, 1987; Koletzko et al. 1989; Sanchez-Medina & Gil, 1996). After supplementation of the formula with nucleotides an increase of LC-PUFA in the plasma and red blood cells was observed (Gil et al. 1986, 1988; DeLucchi et al. 1987; Sanchez-Medina & Gil, 1996). Very probably these effects are related to an influence of dietary nucleotides on desaturation and elongation rates in fatty acid metabolism (Pita et al. 1988). The in vitro and in vivo influences of nucleos(t)ides on liver regeneration have been reported. Five kinds of nucleic acid components – inosine, cytidine, uridine, thymidine and 5'-GMP – were studied in monolayer cultures of hepatocytes concerning their effects on DNA and RNA synthesis. The results reported by Ohyanagi et al. (1996) confirmed the importance of nucleos(t)ides in enhancing nucleic acid metabolism depending on each individual component and suitable concentrations.

The in vitro modulation of cell proliferation and apoptosis (for review see Martin et al. 1994) by individual ribonucleosides has been investigated by Meisel et al. (1998, 1999) using peripheral blood lymphocytes (PBL), HL-60 cells (promyelocytic leukaemia) and Caco-2 cells (colon adenocarcinoma) as human cell culture models. Modulating effects of several ribonucleosides were found in the range of $10^{-7}$ to $10^{-3}$ mol/l. The millimolar concentration was the most effective dosage of all ribonucleosides studied (Table 7). The following ribonucleosides had a marked inhibitory effect on proliferation of PBL and HL-60 cells (Meisel et al. 1998): Ado, m1Ado, m6Ado, m6,2Ado, ip6Ado, m2,2Guo. Except for m1Ado, these ribonucleosides also induced apoptosis of HL-60 cells. A significant apoptotic effect on PBL was found with m6,2Ado and ip6Ado. It is noteworthy that the antiproliferative effect in HL-60 cells, and to some extent the enhancement of apoptosis, revealed a relationship between increasing cell reactivity and the degree of chemical modification of the adenine entity (Table 7) (Meisel et al. 1998). Regarding Caco-2 cell activity, m1Ado, m6Ado, m6,2Ado, ip6Ado and Guo had a pronounced effect as stimulants of apoptosis as well as inhibitors of proliferation. m2Guo induced significant apoptosis of Caco-2 cells but proliferation remained unchanged (Table 7). There is increasing evidence that apoptosis and necrosis represent the extreme ends of a wide range of possible morphological and biochemical deaths (Leist & Nicotera, 1997). The two classical types of cell death can occur simultaneously in cell cultures exposed to the same stimulus. The mode of cell death induced by Ado and several modified ribonucleosides was apoptotic.

To elucidate the possible mechanisms underlying the apoptosis-inducing activities of ribonucleosides, the time-dependent utilization at the extra- and intracellular level and the possibility of a receptor-mediated induction of apoptosis was recently investigated (Meisel et al. 1998). It has been found that ribonucleosides can modulate apoptosis of HL-60 cells via different mechanisms. Ado may follow at least two different pathways in triggering apoptosis of HL-60 cells: (1) mainly through entry into cells mediated by nucleoside transporter and direct activation of as yet unidentified intracellular events; and (2) partially through activation of extracellular A2A-like receptors. Modulation of apoptosis by ip6Ado seems to involve an as yet unidentified extracellular receptor-mediated mechanism. It is not yet clear if an A3 receptor-mediated apoptotic pathway contributes to Ado- or ip6Ado-induced cell death.

It is worth noting that the cancer cell lines HL-60 and Caco-2 were more reactive to apoptotic stimulation than non-malignant PBL (Meisel et al. 1998). Most anticancer drugs produce apoptosis in sensitive cells (Hickman, 1992) involving an increased apoptotic response of cancerous cells and a minimal response from normal cells. For example, micromolar concentrations of purine nucleoside analogues (2-chloro-2'-deoxyadenosine, 9-β-D-arabinosyl-2-fluoroadenine) are reported to be effective as apoptosis-inducing chemotherapeutic agents in the treatment of several types of leukaemia, and it has been shown that their mechanisms of action implicate cellular signalling networks (Robertson et al. 1993).

### Table 7. Comparison of modulating effects of ribonucleosides ($10^{-3}$ mol/l) on cell proliferation and apoptosis assayed by quantitative immunoassay based on BrdU incorporation and DNA fragmentation in cell lysates, respectively

<table>
<thead>
<tr>
<th>Ribonucleoside</th>
<th>Proliferation</th>
<th>Apoptosis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HL-60</td>
<td>Caco-2</td>
</tr>
<tr>
<td>Ado</td>
<td>0.21***</td>
<td>0.96</td>
</tr>
<tr>
<td>m1Ado</td>
<td>0.07**</td>
<td>0.72***</td>
</tr>
<tr>
<td>m6Ado</td>
<td>1.17**</td>
<td>0.61***</td>
</tr>
<tr>
<td>m6,2Ado</td>
<td>0.00*</td>
<td>0.01***</td>
</tr>
<tr>
<td>ip6Ado</td>
<td>0.01***</td>
<td>0.01***</td>
</tr>
<tr>
<td>t6Ado</td>
<td>0.92</td>
<td>0.96</td>
</tr>
<tr>
<td>Guo</td>
<td>0.61**</td>
<td>0.89**</td>
</tr>
<tr>
<td>m1Guo</td>
<td>0.97</td>
<td>0.88***</td>
</tr>
<tr>
<td>m2Guo</td>
<td>1.24</td>
<td>1.01</td>
</tr>
<tr>
<td>m2,2Guo</td>
<td>0.01**</td>
<td>0.90***</td>
</tr>
<tr>
<td>m7Guo</td>
<td>1.26</td>
<td>1.04</td>
</tr>
<tr>
<td>Ino</td>
<td>1.09</td>
<td>1.01</td>
</tr>
<tr>
<td>m1Ino</td>
<td>1.16</td>
<td>0.98</td>
</tr>
<tr>
<td>m7Ino</td>
<td>0.75</td>
<td>1.03</td>
</tr>
<tr>
<td>Cyd</td>
<td>0.59</td>
<td>0.81***</td>
</tr>
<tr>
<td>Urd</td>
<td>1.17</td>
<td>0.87</td>
</tr>
</tbody>
</table>

† Results are expressed as the ratios test/control (mean absorbance$_{test}$/mean absorbance$_{control}$); stimulation: test/control > 1; inhibition: test/control < 1. Mean values of measurements differ with $P < 0.05$; $*P < 0.01$; $**P < 0.001$.

Significant effect already measurable at ribonucleoside concentration of $10^{-4}$ to $10^{-8}$ mol/l. * Accompanied by significant necrosis based on the measurement of DNA fragments in cell culture supernatant (test/control = 1:55, $P < 0.05$). Values taken from Meisel et al. (1998).
RNA and originate from cellular RNA breakdown. It is known that the pattern of these metabolic products is altered in body fluids of individuals suffering from neoplastic diseases, i.e. modified ribonucleosides serve as pathobioc hemical marker molecules for cancer (Borek, 1971; Gehrke & Kuo, 1990; Schlimme et al. 1990a; Schwarzenau et al. 1990). As a vast majority of tumour promoters are potent inhibitors of apoptosis (Wright et al. 1994), it seems unlikely that cancer cells as such produce apoptosis-inducing ribonucleosides. It remains to be clarified if they are released by healthy cells as a reaction against malignant cells. However, this hypothesis is supported by our findings that cancer cell lines (HL-60, Caco-2) are reactive to apoptotic stimulation by modified ribonucleosides (Meisel et al. 1998).

Food-derived inducers of apoptosis may be of significance as exogenous anticarcinogens in the control of malignant cell proliferation where the intestinal tract could be the primary target site for a possible selective apoptotic stimulant against malignant cells.

Technochemical aspects

The pattern of ribonucleosides in mature milk varies only slightly throughout lactation. From experimental findings concerning changes in the contents of ribonucleosides in heat-treated milk (Ott & Schlimme, 1991; Schlimme et al. 1993, 1994, 1998; Martin et al. 1995, 1997, 1998) it can be concluded that the concentrations of cytidine, guanosine and inosine present in raw milk show a multifold increase in milk which has been subjected to thermization and holder pasteurization, whereas the adenosine level decreases. On the other hand, these enzyme- (e.g. adenosine deaminase, alkaline phosphatase) catalysed changes in the content of unmodified ribonucleosides in milk are not observed in milk samples after short- and long-time pasteurization, high temperature pasteurization, ultra-high heating and sterilization. The changes in milk ribonucleoside contents found in these heating regions are mainly attributable to the catalytic activity of the milk enzymes in the course of the heating-up phase.

The level of m1Ado varies only slightly throughout lactation and was found in raw bulk milk to be 0-4 μmol/l. m6Ado, which is not detectable under the pH and temperature conditions prevailing in thermally untreated milk (Ott & Schlimme, 1991), is formed by a Dimroth-rearrangement from m1Ado as a function of heating time and temperature (Ott & Schlimme, 1991; Schlimme et al. 1993, 1994; Martin et al. 1995). This rearrangement follows first order kinetics in the temperature range between 115°C and 150°C with a z-value of 26-8°C and a Q10-value of 2.36 (Schlimme et al. 1994; Martin et al. 1997). The kinetic data found for this rearrangement agree quite well with those found for other thermally induced chemical reactions in milk, e.g. lactulose formation or thiamine loss.

It can be concluded from the viewpoint of dairy technology that these minor constituents are useful as chemical indicators to quantify adulterations of milk and milk products, e.g. thermal milk treatment and – not reviewed in this paper – to distinguish differently processed products, e.g. butter types (Schlimme et al. 1990b, 1996b, 1997a; Meisel et al. 1997).

Conclusion

Nucleosides and nucleotides belong to the group of natural bioactive substances in milk and colostrum that show a species-specific pattern. They are used by the body as exogenous trophochemical sources. The physiological capacity of these compounds in milk is given by the total potentially available amount of nucleosides. They are not only active as metabolites but, furthermore, seem to be important in the regulation of body functions. For example, they enhance antibody responses, contribute to iron absorption in the gut and influence long-chain polyunsaturated fatty acid synthesis in early life. Recent findings on effector properties in human cell model systems imply that modified nucleosides, in particular, inhibit cell proliferation and activate apoptosis. Owing to these biochemical properties of nucleosides and nucleotides, the European Commission allows the supplementation of infant and follow-on formula. Thus, the positive effects of breast milk are also made available to neonates that are not breastfed. Further studies are required to evaluate these findings on the regulative potential of milk nucleosides and of dietary nucleosides in general especially in the early stages of life.

Acknowledgement

E. Schlimme dedicates this work to his mentor Professor Friedrich Cramer.

References


Carver JD, Cox WI & Barness LA (1990) Dietary nucleotide effects upon murine natural killer cell activity and macrophage


© E. Schlimme, D. Martin & H. Meisel 2000